Saifee Mullamitha

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 543 citations · Full text

Cobimetinib Versus Regorafenib, Oncology, Medicine +10

Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume

Gordon C. Jayson, Geoff J.M. Parker, Saifee Mullamitha et al. · Journal of Clinical Oncology · 2004 · 163 citations

Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors

Saifee Mullamitha, N.C. Ton, Geoff J.M. Parker et al. · Clinical Cancer Research · 2007 · 141 citations

Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2

N.C. Ton, Geoff J.M. Parker, Alan Jackson et al. · Clinical Cancer Research · 2007 · 73 citations · Full text

Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer

Gordon C. Jayson, Cong Zhou, Alison Backen et al. · Nature Communications · 2018 · 64 citations · Full text